StreetInsider.com News Articles

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

GENEVA, Aug. 27, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics, or the Company), a global leader in scalable precision neurotherapeutics, today announced the publication of its 2026 half-year report and provided a corporate update.

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Thu, 27 Aug 2026 01:32:00 -0400

Key Highlights

Expanded U.S. commercial capabilities and reach through the build-out of the Company's commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.
Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.
Advanced its European

Form 10-Q Miluna Acquisition Corp For: Jun 30

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921914.html

Form 10-Q Miluna Acquisition Corp For: Jun 30

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921914.html

Form SCHEDULE 13G Miluna Acquisition Corp Filed by: MIZUHO FINANCIAL GROUP INC

Thu, 13 Aug 2026 06:51:00 -0400

si-local-file:///var/storage/secattach/20260813/26916082.html

Form SCHEDULE 13G Miluna Acquisition Corp Filed by: MIZUHO FINANCIAL GROUP INC

Thu, 13 Aug 2026 06:51:00 -0400

si-local-file:///var/storage/secattach/20260813/26916082.html

MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor

Wed, 12 Aug 2026 01:39:00 -0400

GENEVA, Aug. 12, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced that Dr. John Krakauer has joined the Company as a strategic advisor to support its next phase of growth in the United States.

"John has shaped the science behind our platform for years, and his foundational work is central to how we think about recovery," said Zach Henderson, CEO of MindMaze Therapeutics. "As we scale in

MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor

Wed, 12 Aug 2026 01:39:00 -0400

GENEVA, Aug. 12, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced that Dr. John Krakauer has joined the Company as a strategic advisor to support its next phase of growth in the United States.

"John has shaped the science behind our platform for years, and his foundational work is central to how we think about recovery," said Zach Henderson, CEO of MindMaze Therapeutics. "As we scale in

MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor

Wed, 12 Aug 2026 01:39:00 -0400

GENEVA, Aug. 12, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced that Dr. John Krakauer has joined the Company as a strategic advisor to support its next phase of growth in the United States.

"John has shaped the science behind our platform for years, and his foundational work is central to how we think about recovery," said Zach Henderson, CEO of MindMaze Therapeutics. "As we scale in

MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor

Wed, 12 Aug 2026 01:39:00 -0400

GENEVA, Aug. 12, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced that Dr. John Krakauer has joined the Company as a strategic advisor to support its next phase of growth in the United States.

"John has shaped the science behind our platform for years, and his foundational work is central to how we think about recovery," said Zach Henderson, CEO of MindMaze Therapeutics. "As we scale in

MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor

Wed, 12 Aug 2026 01:39:00 -0400

GENEVA, Aug. 12, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced that Dr. John Krakauer has joined the Company as a strategic advisor to support its next phase of growth in the United States.

"John has shaped the science behind our platform for years, and his foundational work is central to how we think about recovery," said Zach Henderson, CEO of MindMaze Therapeutics. "As we scale in